

SCRI Trials and Trial Regimen Updates

The following updates were completed between Aug. 22 – Sept. 18. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.

For questions about these trials and regimens, please contact SCRIKMEMRedits@McKesson.com.

New Builds Completed

Study Number	Notes for New Build
25018	USOR 25018 GI 411 Phase 3 HLX22 or Placebo + Trastuzumab + Oxaliplatin + Capecitabine + Pembrolizumab or Placebo Q21D - v3.0 17DEC2024 USOR 25018 GI 411 Phase 3 HLX22 or Placebo + Trastuzumab + Oxaliplatin + Capecitabine Q21D - v3.0 17DEC2024
24321	USOR 24321 LYM 260 Phase 3 Golcadomide + Rituximab Q28D - 11FEB2025 USOR 24321 LYM 260 Phase 3 Rituximab + Bendamustine Q28D - 11FEB2025 USOR 24321 LYM 260 Phase 3 Rituximab + CHOP Q21D - 11FEB2025 USOR 24321 LYM 260 Phase 3 Rituximab + Lenalidomide Q28D - 11FEB2025
24059	USOR 24059 GYN 135 Phase 2 Part A R-DXd Q21D - v2.0 05FEB2025
24311	USOR 24311 BRE 460 Phase 1 Safety Cohort A1 Sacituzumab govitecan Q14D - 19NOV2024
24094	USOR 24094 BRE 457 Phase 3 Arm A PF-07220060 + Letrozole Q28D - 03SEP2024 USOR 24094 BRE 457 Phase 3 Arm B Letrozole + CDK4/6 Inhibitor Q28D - 03SEP2024
24185	USOR 24185 BRE 448 Phase 3 Arm A sac-TMT (MK-2870) Q84D 22NOV2024 USOR 24185 BRE 448 Phase 3 Arm B sac-TMT (MK-2870) + Pembrolizumab Q84D 22NOV2024 USOR 24185 BRE 448 Phase 3 Arm C Gemcitabine + Carboplatin Q84D 22NOV2024 USOR 24185 BRE 448 Phase 3 Arm C Nab-paclitaxel Q84D 22NOV2024 USOR 24185 BRE 448 Phase 3 Arm C Paclitaxel Q84D 22NOV2024
24266	USOR 24266 CLL 65 Phase 3 Arm A Sonrotoclax + Obinutuzumab Q28D - 13FEB2025 USOR 24266 CLL 65 Phase 3 Arm B Sonrotoclax + Rituximab Q28D - 13FEB2025 USOR 24266 CLL 65 Phase 3 Arm C Sonrotoclax + Obinutuzumab Q28D - 13FEB2025 USOR 24266 CLL 65 Phase 3 Arm D Venetoclax + Rituximab Q28D - 13FEB2025
24232	USOR 24232 LUN 581 Phase 3 Arm A NVL-655 Q28D - v2.0 06JUN2025 USOR 24232 LUN 581 Phase 3 Arm B Alectinib Q28D - v2.0 06JUN2025

Updated Reference Information

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
24326	PM v3.0 29Apr2025	Regimen Comments; Admin and Observation	Updated Drug Instructions
24312	PA 2.0; 25 July 2025	Regimen Comments: Admin	Updated Drug Instructions and Premedication
24312	PM v1.1 04Mar2025	N/A	Updated drug; Admin and Prep
24288	PM v1.0; 20 August 2025	N/A	Updated drug instructions
24169	PA 2, 14APRIL2025	Regimen Comments: Admin	Updated Drug Instructions
24150	PCL; 01 August 2025 PCL; 11 August 2025	N/A	Updated drug frequency
24030	Version 3.0; 01 July 2025	Regimen comments; Admin	Updated drug instructions and premedication
23340	PM v5.0; 13 August 2025	N/A	Updated Dose/Form and instructions
23328	Version 2.0; 03MAR2025	N/A	Updated drug instructions
23302	PM v2.0; 16th April 2025	N/A	Updated drug instructions
23245	DIL; 27 August 2025	N/A	New arms
23180	PA v3.0, 27May2025	Regimen Comments; Observation	Updated drug instructions and premedication
23166	DIL; 14 August 2025	N/A	Closed arms
23116	Amendment v6, 29APR2025	Regimen Comments: Admin	Updated Admin/Prep and drug instructions
23084	PM v3.0; 21st August 2025	N/A	Updated Drug instructions

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
22242	Version 6.0, 02MAY2025	N/A	Updated drug; instructions, premedication, and frequency
22095	PA v9.0: 01 May 2025	Regimen comments: Admin	Updated drug instructions
22026	PA8: 25 Feb 2025	Regimen comments: Admin, Prophylaxis, Premedication	Updated drug; instructions and premedication
22026	Version 7.0; 07 August 2025 PACL; 11 August 2025	Regimen Comments; Admin and Observation	Updated drug; Drug form, instructions, premedication, procurement
24326	Amendment 1 Version 2; 19MAR2025.	Regimen comments; admin	Updated drug; premedication New Arms
24259	PM v2.0; 13th Feb 2025	N/A	Updated drug; predication
23292	PA v18.0; 24 Feb 2025	Regimen Comments; Admin	Updated drug; premedication New arms
24130	PCL; 16 June 2025 PA v4.0; 26 June 2025	N/A	Updated drug instructions and premedication